Tallinn Children's Hospital Foundation
- Address
- lock Available on a paid plan
Neoplasms and Pediatric Hematology
At Tallinn Children's Hospital Foundation, clinical research in this area focuses on acute lymphoblastic leukaemia in infants, children, and young adults. The trials are designed to improve survival and quality of life while also helping identify which patients may benefit from newer treatment approaches, including immunotherapy.
- Studying acute lymphoblastic leukaemia to improve long-term outcomes
- Evaluating new ways to support treatment effectiveness and survival
- Exploring whether selected patients could benefit from novel immunotherapy
This work combines treatment evaluation with efforts to better understand disease behavior and reduce treatment-related harm in young patients.
Bacterial Infections and Mycoses and Infectious Disease Care
Research in anesthesiology and intensive care at this site also includes studies of serious bacterial infections, especially nosocomial infection and pneumonia in children. The aim is to assess the safety and tolerability of treatments used for these infections and support better care for hospitalized pediatric patients.
- Investigating treatment options for nosocomial pneumonia
- Assessing safety and tolerability of antibacterial therapy
- Supporting improved management of hospital-acquired infections
These trials address important questions about infection control and treatment effectiveness in a hospital setting, where rapid and reliable care is especially important.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 16 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Karolinska University Hospital1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Tallinn Children's Hospital Foundation
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 1, open-label, non-comparative, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric participants with nosocomial pneumonia | Merck Sharp & Dohme LLC | Phase I | Not Recruiting | Feb 2020 | May 2024 |
IMP list
lock Showing 1 of 16 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Blinatumomab | 1 | Unknown | 2020-07-13 | 2020-07-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.